A new trading day began on Monday, with BioAtla Inc (NASDAQ: BCAB) stock price down -6.41% from the previous day of trading, before settling in for the closing price of $0.33. BCAB’s price has ranged from $0.28 to $4.02 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -58.37% over the last five years. Meanwhile, its annual earnings per share averaged 40.93%. With a float of $49.42 million, this company’s outstanding shares have now reached $58.02 million.
The firm has a total of 65 workers. Let’s measure their productivity. In terms of profitability, gross margin is 93.41%, operating margin of -678.7%, and the pretax margin is -643.92%.
BioAtla Inc (BCAB) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of BioAtla Inc is 14.35%, while institutional ownership is 34.50%.
BioAtla Inc (BCAB) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.39 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 40.93% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.02% during the next five years compared to -25.30% drop over the previous five years of trading.
BioAtla Inc (NASDAQ: BCAB) Trading Performance Indicators
Here are BioAtla Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.70, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.41 in one year’s time.
Technical Analysis of BioAtla Inc (BCAB)
Analysing the last 5-days average volume posted by the [BioAtla Inc, BCAB], we can find that recorded value of 1.05 million was better than the volume posted last year of 1.01 million. As of the previous 9 days, the stock’s Stochastic %D was 11.85%. Additionally, its Average True Range was 0.05.
During the past 100 days, BioAtla Inc’s (BCAB) raw stochastic average was set at 1.08%, which indicates a significant decrease from 11.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 91.76% in the past 14 days, which was lower than the 120.72% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5351, while its 200-day Moving Average is $1.4574. Now, the first resistance to watch is $0.3312. This is followed by the second major resistance level at $0.3575. The third major resistance level sits at $0.3731. If the price goes on to break the first support level at $0.2893, it is likely to go to the next support level at $0.2737. Now, if the price goes above the second support level, the third support stands at $0.2474.
BioAtla Inc (NASDAQ: BCAB) Key Stats
With a market capitalization of 17.69 million, the company has a total of 48,346K Shares Outstanding. Currently, annual sales are 0 K while annual income is -123,460 K. The company’s previous quarter sales were 11,000 K while its latest quarter income was -10,590 K.
